[{"id":"80c27074-d3d8-4725-96f3-fbf2b5630d87","acronym":"","url":"https://clinicaltrials.gov/study/NCT05584670","created_at":"2022-10-18T14:57:14.377Z","updated_at":"2024-07-02T16:34:59.740Z","phase":"Phase 1/2","brief_title":"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05584670","lead_sponsor":"Sanofi","biomarkers":" MSI","pipe":" | ","alterations":" HER-2 negative","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • SAR445877"],"overall_status":"Recruiting","enrollment":" Enrollment 285","initiation":"Initiation: 11/29/2022","start_date":" 11/29/2022","primary_txt":" Primary completion: 01/19/2027","primary_completion_date":" 01/19/2027","study_txt":" Completion: 09/27/2028","study_completion_date":" 09/27/2028","last_update_posted":"2024-05-31"}]